Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

BioMarin PKU Drug Has Mixed Results in Phase 3 Study

By Drug Discovery Trends Editor | March 21, 2016

​BioMarin Pharmaceutical’s drug for the rare, inherited disease phenylketonuria (PKU) produced mixed results in an eight-week Phase 3 study, the company announced Monday.

The daily injection, pegvaliase, met the main study goal of reducing toxic-buildup levels of phenylalanine (Phe) in the blood of PKU patients by 62 percent compared with a placebo. However, the drug did not show significant cognitive improvement in attentiveness or mood.

BioMarin shares fell 4 percent in premarket trading on Monday.

PKU is a genetic disorder that increases the levels of the amino acid, phenylalanine, found in most protein-containing food. If PKU is not treated, phenylalanine can build up to harmful levels in the body, causing intellectual disability and other serious health problems.

Currently, PKU is managed with a strict diet of limited protein and by taking a PKU formula — a special nutritional supplement — for life to ensure necessary protein intake (without phenylalanine). BioMarin’s currently approved pill, Kuvan, is also used in conjunction with a restrictive diet to manage the disorder.

The new injectable, pegvaliase, is designed to be more potent than Kuvan and is intended to eliminate this dietary component.

BioMarin said it is encouraged by additional study data showing improved neurocognitive symptoms in those treated with pegvaliase for a longer time period. The company said it expects to submit a marketing application for the daily injectable later this year, subject to more discussions with the FDA.

“Treatment with pegvaliase has resulted in dramatic phenylalanine decreases down to within normal levels which have not been achievable in the past with other PKU treatment options,” said Hank Fuchs, M.D., chief medical officer at BioMarin.

About 40 percent of patients treated with pegvaliase experienced hypersensitivity reactions compared with 14 percent of placebo patients. There were no reported cases of anaphylaxis reported during the Phase 3 study (however, anaphylaxis was reported in 8 percent of patients across the entire Phase 3 program).

PKU is diagnosed in about 50,000 patients in the developed world, and affects around 20,000 people in the U.S.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE